Clinical Trials Browser

Adenocarcinoma Of Esophagus × tremelimumab × 1 year × Clear all

NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus